Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pharmacokinetics Study of Cefazolin in Hemodialysis (CEFAZODIAL)
Sponsor: University Hospital, Tours
Summary
In chronic hemodialysis patients, bacteremia is most commonly caused by dialysis catheter infections. It is estimated that the vast majority (52-84%) of these infections are due to Gram-positive cocci, particularly Staphylococcus aureus (21-43%). Penicillin M (oxacillin and cloxacillin in France) is the reference beta-lactam for the treatment of invasive methicillin-sensitive S. aureus (MSSA) infections, but has not shown a prognostic benefit in large retrospective cohorts comparing penicillin M and cefazolin, at the expense of more frequent adverse events. Dosage in the chronic hemodialysis population is unclear because it is based on old studies.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2023-11-20
Completion Date
2025-12
Last Updated
2025-12-05
Healthy Volunteers
No
Interventions
Blood samples
For all subjects (short kinetics): * Pre-injection of cefazolin * Start of next dialysis * Two hours after start of subsequent dialysis * End of next dialysis, before cefazolin administration Only in hospitalized subjects (rich kinetics): * 30 minutes, 1h and 2h after cefazolin injection, to describe the cefazolin peak and possible post-dialysis rebound * 12h, 24h and 36h after cefazolin injection, to better describe cefazolin elimination and distribution
Locations (2)
Department of hemodialysis, University Hospital of Tours
Orléans, France
Department of hemodialysis, University Hospital of Tours
Tours, France